Alzheimer’s Disease: Have We Been Focusing on the Wrong Proteins?

Authors

  • Ryan Gotesman McMaster University

Abstract

NA

References

Sabuncu MR, Fischl B. The dynamics of cortical and hippocampal atrophy in alzheimers disease. Arch Neurol. 2011;68(8):1040–8.

Querfurth HW, Laferla FM. Alzheimer’s Disease. N Engl J Med. 2010;362(4):329–44.

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement. 2007;3(3):186–91.

Cole SL, Vassar R. The Alzheimer’s disease Beta-secretase enzyme, BACE1. Mol Neurodegener [Internet]. 2007;2(1):22. Available from: http://molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-2-22

Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, et al. Structural conversion of neurotoxic amyloid-β(1-42) oligmers to fibrils. Nat Struct Mol Biol. 2010;17(5):561–7.

Seino Y, Kawarabayashi T, Wakasaya Y, Watanabe M, Takamura A, Yamamoto-Watanabe Y, et al. Amyloid β accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model. J Neurosci Res. 2010;88(16):3547–54.

Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci [Internet]. Nature Publishing Group; 2015;17(1):22–35. Available from: http://dx.doi.org/10.1038/nrn.2015.1

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term Effects of Aβ42 Immunisation in Alzheimer’s disease: Follow-up of a Randomised, Placebo-controlled Phase I Trial. Lancet. 2008;372(9634):216–23.

Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. Arch Neurol. 2012;69(2):198–207.

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. Diabetes Care. 2013;369(4):341–50.

Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010;67(3):353–64.

Tariot PN. Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease. Arch Gen Psychiatry [Internet]. 2011;68(8):853. Available from: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archgenpsychiatry.2011.72

Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, Lafaille JJ, et al. Neuroprotective Effects of Lithium: Implications for the Treatment of Alzheimer’s Disease and Related Neurodegenerative Disorders. ACS Chem Neurosci [Internet]. 2014;5(7):443–50. Available from: http://pubs.acs.org/doi/abs/10.1021/cn5000309nhttp://www.cell.com/article/S0092867413014815/fulltext

Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: Improvements and limitations. Diabetes, Obes Metab. 2011;13(8):677–84.

Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ. 2001;322(7299):1389–93.

Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care [Internet]. 2004;27(10):2540–53. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp

Kuusisto J, Koivisto K, Mykkänen L, Helkala E, Vanhanen M, Hänninen T, et al. Association between features of the insulin resistance syndrome and Alzheimer ’ s disease independently of apolipoprotein E4 phenotype : cross sectional population based study. BMJ. 1997;315(October):1045–9.

Ishii K. PET approaches for diagnosis of dementia. AJNR Am J Neuroradiol [Internet]. 2014;35(11):2030–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23945233

Ott A, Stolk RP, van Harskamp F, Pols HAP, Hofman A, Breteler MMB. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 2011;53(9):1937–97.

Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study. Diabetologia [Internet]. 2009;52(6):1031–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19280172

Grünblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem. 2007;101(3):757–70.

Monte SM De. Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimer ’ s Disease. 2012;72(1):49–66.

Devi L, Alldred MJ, Ginsberg SD, Ohno M. Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer’s disease. PLoS One. 2012;7(3):1–8.

Dandona P, Mohamed I, Ghanim H, Sia CL, Dhindsa S, Dandona S, et al. Insulin suppresses the expression of amyloid precursor protein, presenilins, and glycogen synthase kinase-3beta in peripheral blood mononuclear cells. J Clin Endocrinol Metab [Internet]. 2011;96(6):1783–8. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3100748&tool=pmcentrez&rendertype=abstract

Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 2001;21(8):2561–70.

Li B, Ryder J, Su Y, Moore SA, Liu F, Solenberg P, et al. Overexpression of GSK3BS9A resulted in tau hyperphosphorylation and morphology reminiscent of pretangle-like neurons in the brain of PDGSK3B transgenic mice. Transgenic Res. 2004;13:385–96.

Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov. 2004;3(6):479–87.

Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, et al. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell. 2001;105(6):721–32.

Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology [Internet]. 2008;70(6):440–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17942819

Craft S. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment. Arch Neurol [Internet]. 2012;69(1):29. Available from: http://archneur.jamanetwork.com/article.aspx?doi=10.1001/archneurol.2011.233

Hsu CC, Wahlqvist ML, Lee MS, Tsai HN. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimer’s Dis. 2011;24(3):485–93.

Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, Other Antidiabetic Drugs, and Risk of Alzheimer’s Disease: A Population-Based Case-Control Study. J Am Geriatr Soc [Internet]. 2012;60(5):916–21. Available from: http://doi.wiley.com/10.1111/j.1532-5415.2012.03916.x

Vol. 2 No. 1 (2017)

Downloads

Published

2017-08-16

Issue

Vol. 2 No. 1 (2017): Catalyst: Facets of Biochemistry and Biomedical Sciences

Section

Perspectives

License

Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).